HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc07-0992v1 30/11/2934    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Avignon, A. Articles by Dupuy, A. M. Search for Related Content PubMed PubMed Citation Articles by Avignon, A. Articles by Dupuy, A. M. Social Bookmarking                What's this?

Osteoprotegerin: A Novel Independent Marker for Silent Myocardial Ischemia in Asymptomatic Diabetic Patients

¹ CHU Montpellier, Metabolic Diseases Department, Lapeyronie Hospital, Montpellier, France
² UFR de Médecine, EA 4188, Université Montpellier, Montpellier, France
³ CHU Montpellier, Service de Cardiologie B, Hôpital Arnaud de Villeneuve, Montpellier, France
⁴ CHU Montpellier, Service de Médecine Nucléaire, Hôpital Lapeyronie, Montpellier, France
⁵ CHU Montpellier, Service de Biochimie, Hôpital Lapeyronie, Montpellier, France
⁶ UFR de Médecine, EA 4188, Université Montpellier, Montpellier, France

Address correspondence and reprint requests to Antoine Avignon, Metabolic Disease Department, Lapeyronie Hospital, 371, Av Doyen G. Giraud, 34295, Montpellier Cedex 5, France. E-mail: a-avignon{at}chu-montpellier.fr

OBJECTIVE—We sought to evaluate osteoprotegerin, an inhibitor of osteoclastogenesis involved in atherosclerosis, and other novel risk factors as predictive markers of silent myocardial ischemia (SMI).

RESEARCH DESIGN AND METHODS—A total of 465 consecutive diabetic patients with more than one additional risk factor were evaluated for SMI using stress myocardial perfusion imaging (MPI). We studied the association of SMI (positive stress electrocardiogram and/or abnormal MPI) with osteoprotegerin, other novel risk factors (lipoprotein[a], homocysteine, adiponectin, C-reactive protein, and fibrinogen), and conventional risk factors (total, LDL, and HDL cholesterol and triglycerides).

RESULTS—A total of 92 patients were diagnosed with SMI. Of the six novel markers, osteoprotegerin was the only one associated with SMI; the relative risk (RR) of SMI in patients with osteoprotegerin values above the 75th percentile was 3.19 (95% CI 1.99–5.18; P < 0.001) in comparison with those with osteoprotegerin below the 75th percentile. In univariate analyses, the other plasma markers significantly associated with SMI were higher triglycerides (P = 0.04) and lower HDL cholesterol (P = 0.02). The association of osteoprotegerin with SMI remained significant after correcting for other variables associated with SMI at P < 0.15 in univariate analysis (RR 3.95 [95% CI 2.21–7.06]; P < 0.0001). The association of osteoprotegerin with SMI was observed in male (P < 0.0001) and female (P = 0.03) patients, in type 1 (P = 0.002) and type 2 (P = 0.0004) diabetic patients, in patients with (P = 0.0004) or without (P = 0.03) nephropathy, and in patients without (P < 0.0001) but not with (P = 0.2) peripheral arterial disease.

CONCLUSIONS—Osteoprotegerin measurement, together with other conventional factors, can help to better define the diabetic population with an increased likelihood for SMI.

Abbreviations: Apo, apolipoprotein • CAD, coronary artery disease • CRP, C-reactive protein • ECG, electrocardiogram • hs-CRP, high-sensitivity CRP • HPLC, high-performance liquid chromatography • MPI, myocardial perfusion imaging • PAD, peripheral arterial disease • SMI, silent myocardial ischemia

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. F Escobar-Morreale, J. I Botella-Carretero, M. A. Martinez-Garcia, M. Luque-Ramirez, F. Alvarez-Blasco, and J. L S. Millan Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome Eur. J. Endocrinol., September 1, 2008; 159(3): 225 - 232. [Abstract] [Full Text] [PDF]